San Diego—Patients with stage IV non-small cell lung cancer (NSCLC) with the highest out-of-pocket costs for oral tyrosine kinase inhibitors (TKIs) have double the risk for death of patients with lower costs, according to a study from Fred Hutchinson Cancer Research Center, in Seattle.
Patients who have higher out-of-pocket (OOP) costs are less likely to fill their prescriptions and to remain on therapy than those with lower costs, the researchers said, presenting the study at the American